105 related articles for article (PubMed ID: 26881321)
1. Molecular testing patterns in metastatic non-small cell lung cancer.
MacLean E; Louder A; Saverno K; Smith G; Mardekian J; Brunis C; Ward M; Sweetman R; Pasquale M
Am J Manag Care; 2016 Feb; 22(2):e60-7. PubMed ID: 26881321
[TBL] [Abstract][Full Text] [Related]
2. Biopsy Procedures and Molecular Testing Utilization and Related Costs in Patients with Metastatic Lung Cancer.
Shinde R; Cao X; Kothari S
J Manag Care Spec Pharm; 2016 Oct; 22(10):1194-203. PubMed ID: 27668568
[TBL] [Abstract][Full Text] [Related]
3. Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
Liang Y; Wakelee HA; Neal JW
Clin Lung Cancer; 2015 Sep; 16(5):366-73. PubMed ID: 25665893
[TBL] [Abstract][Full Text] [Related]
4. EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?
Hendriks LE; Smit EF; Vosse BA; Mellema WW; Heideman DA; Bootsma GP; Westenend M; Pitz C; de Vries GJ; Houben R; Grünberg K; Bendek M; Speel EJ; Dingemans AM
Lung Cancer; 2014 Apr; 84(1):86-91. PubMed ID: 24529684
[TBL] [Abstract][Full Text] [Related]
5. Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?
Sacher AG; Le LW; Lau A; Earle CC; Leighl NB
Cancer; 2015 Aug; 121(15):2562-9. PubMed ID: 25891153
[TBL] [Abstract][Full Text] [Related]
6. Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers.
Chawla A; Peeples M; Li N; Anhorn R; Ryan J; Signorovitch J
J Med Econ; 2018 Jun; 21(6):543-552. PubMed ID: 29295635
[TBL] [Abstract][Full Text] [Related]
7. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
8. Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.
Hames ML; Chen H; Iams W; Aston J; Lovly CM; Horn L
Lung Cancer; 2016 Feb; 92():29-34. PubMed ID: 26775593
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans.
Ramsey SD; Scoggins JF; Blough DK; McDermott CL; Reyes CM
J Manag Care Pharm; 2009 Oct; 15(8):659-68. PubMed ID: 19803555
[TBL] [Abstract][Full Text] [Related]
10. Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy.
Goldman JW; Shi P; Reck M; Paz-Ares L; Koustenis A; Hurt KC
Clin Lung Cancer; 2016 Jan; 17(1):80-4. PubMed ID: 26432508
[TBL] [Abstract][Full Text] [Related]
11. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.
Alden RS; Mandrekar SJ; Oxnard GR
Chin Clin Oncol; 2015 Sep; 4(3):37. PubMed ID: 26408304
[TBL] [Abstract][Full Text] [Related]
12. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer.
Lozano MD; Labiano T; Echeveste J; Gurpide A; Martín-Algarra S; Zhang G; Sharma A; Palma JF
Cancer Cytopathol; 2015 Apr; 123(4):230-6. PubMed ID: 25529460
[TBL] [Abstract][Full Text] [Related]
13. Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer.
Sun JM; Rampal S; Lee G; Lee J; Choi YL; Parasuraman B; Guallar E; Cho J; Shim YM
Lung Cancer; 2013 May; 80(2):191-6. PubMed ID: 23384673
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
Narita Y; Matsushima Y; Shiroiwa T; Chiba K; Nakanishi Y; Kurokawa T; Urushihara H
Lung Cancer; 2015 Oct; 90(1):71-7. PubMed ID: 26259876
[TBL] [Abstract][Full Text] [Related]
15. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
Schuler M; Wu YL; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist LV; Massey D; Zazulina V; Yang JC
J Thorac Oncol; 2016 Mar; 11(3):380-90. PubMed ID: 26823294
[TBL] [Abstract][Full Text] [Related]
16. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
Nishiyama A; Katakami N; Yoshioka H; Iwasaku M; Korogi Y; Hata A; Takeshita J; Otsuka K; Nishino K; Uchida J; Okuyama T; Namba Y; Mori M; Fujita S; Morita S
Lung Cancer; 2015 Sep; 89(3):301-5. PubMed ID: 26141215
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated With Receipt of Molecular Testing and its Impact on Time to Initial Systemic Therapy in Metastatic Non-Small Cell Lung Cancer.
Osazuwa-Peters OL; Wilson LE; Check DK; Roberts MC; Srinivasan S; Clark AG; Crawford J; Chrischilles E; Carnahan RM; Campbell WS; Cowell LG; Greenlee R; Abbott AM; Mosa ASM; Mandhadi V; Stoddard A; Dinan MA
Clin Lung Cancer; 2023 Jun; 24(4):305-312. PubMed ID: 37055337
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
Lopez-Chavez A; Thomas A; Rajan A; Raffeld M; Morrow B; Kelly R; Carter CA; Guha U; Killian K; Lau CC; Abdullaev Z; Xi L; Pack S; Meltzer PS; Corless CL; Sandler A; Beadling C; Warrick A; Liewehr DJ; Steinberg SM; Berman A; Doyle A; Szabo E; Wang Y; Giaccone G
J Clin Oncol; 2015 Mar; 33(9):1000-7. PubMed ID: 25667274
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
Minami S; Kijima T; Hamaguchi M; Nakatani T; Koba T; Takahashi R; Takeuchi Y; Kida H; Nagatomo I; Yamamoto S; Tachibana I; Komuta K; Kawase I
Lung Cancer; 2013 Nov; 82(2):271-5. PubMed ID: 23993733
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
